AstraZeneca's new entrant

Synopsis

AstraZeneca, the Anglo-Swedish pharmaceuticals company, appoints Pascol Soriot from Roche as its new chief executive. This significant leadership change raises questions about the future direction of the struggling drugs company. Lex's Stuart Kirk and Vincent Boland provide insights into the implications of Soriot's appointment and what it means for AstraZeneca's performance in the competitive pharmaceutical landscape. The commentary highlights the challenges faced by the company and the potential strategies Soriot may implement to revitalize its operations.